• Print
  • Share
Skip Navigation LinksHome   /   Studies   /   Clinical Trials   /   BMT CTN   /   Protocols   /   Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia
Study #: BMT CTN 0805 / SWOG 0805
Study Status: Open To Accrual (Enrolling)


Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia

This study is also known as:

This study is also known as: Collaboration CommentsThis collaborative study is led by SWOG with active involvement of BMT CTN and ECOG representatives on the Protocol Team.



Abstracts:


Publication(s):
PMCID:  
OBJECTIVES
1.1 To test whether the relapse-free survival after allogeneic stem cell transplantation among
Philadelphia chromosome positive and/or BCR/ABL positive acute lymphoblastic leukemia (ALL) patients given an intensive short-term chemotherapy regimen of hyper-
CVAD in combination with the tyrosine kinase inhibitor dasatinib is sufficiently high to warrant further investigation.
1.2 To test whether the continuous complete remission rate for previously untreated
Philadelphia chromosome positive and/or BCR/ABL positive acute lymphoblastic leukemia (ALL) patients given an intensive short-term chemotherapy regimen of hyper-
CVAD in combination with the tyrosine kinase inhibitor dasatinib is sufficiently high to warrant Phase III investigation.
1.3 To investigate in a preliminary manner the relative effectiveness of MRD detection using real-time quantitative PCR for BCR/ABL versus flow cytometry to predict the outcome of patients treated by the hyper-CVAD + dasatinib regimen and/or allogeneic stem cell transplant.
1.4 To estimate the frequency and severity of toxicities of the intensive short-term chemotherapy regimen in these patients.
1.5 To estimate the overall survival of all patients on this study.
 
 

Study Contact

Sandi Jo McMillan (SWOG Protocol Coordinator) smcmillan@swog.org
Amy Foley (BMT CTN) afoley@nmdp.org
 

Learn More

Additional information on this protocol is available through the BMT CTM Website at:

 


Blood and Marrow Transplant
Last Updated: 4/25/2013 2:39 PM